patient-advocacy
(11)
The Small Agency That Learned to Be Everywhere
For forty years, MCS Health has sold a peculiar advantage: the attention of a specialist shop with the reach of a network. Its 2025 reset shows what happens when a boutique decides scale should be borrowed, not owned.
The Health Agency That Bought the Missing Pieces
JPA Health began with an unfashionable idea: healthcare messages work better when the people who understand policy, patients, science and data sit at the same table. Then it spent two years buying the chairs it was missing.
RevHealth Put the Boring Parts on Fast-Forward
A private-equity transition dented revenue. RevHealth's answer was not a louder campaign, but a quieter reinvention of the agency workflow - putting medical, access, creative and AI in the same room before the brief hardens.
The People Missing From the Drug-Development Meeting
VOZ Advisors built a business around a costly corporate blind spot: medicines are often planned in rooms where the people expected to live with them are missing.
The Six-Week Reversal: How Cullari Communications Global Turns Trust Into Infrastructure
The Hershey consultancy does not sell attention for its own sake. It builds coalitions around the people whose trust a health company cannot manufacture - and measures what happens next.
The Firm Between the Hearing Room and the Church Basement
Pyxis Partners has built a business translating between Washington's health-policy rooms and communities that have good reasons to distrust them. Its real product is not access alone. It is the patient work of making access travel both ways.
The Most Important Person in the Picture Is Not the Patient
Living in the Light has spent more than a decade making rare-disease stories less clinical and more human. Its method begins with a small but radical edit: move the diagnosis out of the center of the frame.
JFK Communications Knows the Most Dangerous Word in Health PR Is ‘Breakthrough’
The boutique agency built a business around a hard editorial problem: making consequential science clear without making it careless.
The Scientists Had the Breakthrough. TellMed Had to Make Anyone Care.
A New Jersey agency found a business in the awkward distance between a scientific result and a human reaction. Its product is not publicity so much as translation - with enough regulatory discipline to survive the trip.
Biotechnology Innovation Organization
The Biotechnology Innovation Organization (BIO) is the world's largest trade association for the biotech industry, representing more than 1,000 companies, research institutions and state and regional bio centers across the United States and 30-plus countries. Founded in 1993 and headquartered in Washington, D.C., BIO lobbies on drug pricing, intellectual property, regulation and biosecurity, and runs the BIO International Convention - the industry's flagship annual dealmaking and networking event. Led since 2024 by President and CEO John F. Crowley, a rare-disease entrepreneur whose own children have Pompe disease, BIO's stated mission is to advance a 'bio revolution' that cures patients, protects the climate and nourishes humanity.
Novellia
Novellia is a New York-based digital health company that lets patients pull together their complete medical history from more than 50,000 U.S. healthcare systems into one free app, then choose whether to share de-identified versions of that data with drug companies and researchers. Using proprietary natural language processing, Novellia turns messy, unstructured clinical text - physician notes, lab narratives, diagnostic reports - into clean, research-ready longitudinal datasets. The result is a two-sided model: patients regain control of their records at no cost, while life sciences organizations get higher-quality, patient-consented real-world data than the fragmented claims-based datasets they buy today.